Boehringer Ingelheim disclosed discovery of cGAS inhibitors aimed at autoinflammatory interferonopathies, pulmonary fibrosis, MASH, systemic sclerosis and lupus. The disclosure describes chemical matter that modulates cyclic GMP‑AMP synthase (cGAS), a DNA‑sensing enzyme upstream of type I interferon signaling. Company materials argue cGAS inhibition provides a disease‑modifying approach for disorders driven by aberrant nucleic acid sensing. The summary highlights that cGAS is a key innate immune sensor and that translating inhibitors into patients will require balancing suppression of pathological inflammation without impairing antiviral defense.